Redwood City, California-based Third Rock Ventures, LLC, a healthcare venture firm, recently announced $45 million in Series A financing to launch the biotechnology start-up company Pliant Therapeutics, Inc., with a mandate to discover, develop, and commercialize breakthrough drug treatments for fibrotic diseases. Pliant’s product engine has the potential to address the needs…
New IPF Therapy Is Goal of Pliant Therapeutics, a Start-up Focusing on Fibrotic Diseases
Learn more about IPF:https://bit.ly/1QiRmr3…
“Professor Ulrich Costabel, from the Department of Pneymonology and Allergology, Ruhrlandklinik, Essen, discusses some questions and possible causes of idiopathic pulmonary fibrosis (IPF).” Read more about pulmonary fibrosis:Â https://bit.ly/1lfMsiZ…
Learn more about pulmonary fibrosis:Â https://bit.ly/1lfMsiZ…
https://www.youtube.com/watch?v=f_drG3aijSU “Kearni Warren sits down with Gerard Criner, M.D. to learn more about pulmonary fibrosis and some of the treatment options for patients.” Learn more about pulmonary fibrosis:Â https://bit.ly/1lfMsiZ…
Country music artist Joe Nichols is partnering with Boehringer Ingelheim to raise awareness about idiopathic pulmonary fibrosis (IPF). Nichols’ father, Michael Nichols, suffered with IPF symptoms for three years before receiving the diagnosis, and he died from the condition at age 46. As part of a national education campaign called Breathless: A…
Learn more about idiopathic pulmonary fibrosis:Â https://bit.ly/1QiRmr3…
Last week’s hot topic on pulmonary fibrosis was Traditional Chinese Medicine Eased Inflammation, Fibrosis in Animal PF Model written by Magdalena Kegel. This articles focus on a study from the University of Madras, India, which showed that celastrol — a component of an extract from the Thunder…
Morristown, New Jersey-based Capsugel, a provider of empty two-piece hard capsules and an innovator of drug delivery systems, and Pulmatrix, of Lexington, Massachusetts — a clinical-stage biopharmaceutical company and developer of inhaled therapies for treating pulmonary fibrosis and other pulmonary diseases with its patented iSPERSE technology, are collaborating to develop…
Apellis Pharmaceuticals, Inc., recently announced that it has completed a $47.1 million Series D preferred stock financing, which will be used to advance clinical trials into the company’s complement immunotherapy programs for diseases that include idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). The complement system is part of…
